Drug intelligence / Profile preview

lirafugratinib

Development stage: Approved
Lead developer: Elevar Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

Lirafugratinib is an investigational, orally administered, highly selective and irreversible small-molecule inhibitor of fibroblast growth factor receptor 2. It was designed to inhibit oncogenic FGFR2 fusions, rearrangements, and selected kinase-domain resistance mutations while minimizing inhibition of FGFR1, FGFR3, and FGFR4. The drug is being developed for previously treated FGFR2-driven cholangiocarcinoma and for other advanced solid tumors harboring FGFR2 fusions or rearrangements. Relay Therapeutics originated the program and granted Elevar Therapeutics worldwide development and commercialization rights in December 2024. ([ir.relaytx.com](https://ir.relaytx.com/news-releases/news-release-details/relay-therapeutics-and-elevar-therapeutics-announce-exclusive/))

Brand names: LYRFIGTU
Other names: lirafugratinib

Targets

FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR4 (Fibroblast growth factor receptor 4)

Beyond the preview

Go deeper on lirafugratinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lirafugratinib.